Articles tagged with: Clodronate
Today was the third day of the American Society of Clinical Oncology (ASCO) annual meeting, and the morning was filled with oral presentations about important myeloma-related studies. Most of the talks were about potential new anti-myeloma drugs.
This update summarizes the presentations about panobinostat (Farydak), obatoclax, Treanda (bendamustine), and MLN9708 (ixazomib), which are all being developed as potential multiple myeloma treatments. In addition, the update includes a recap of a presentation about the safety of long-term bisphosphonate use. …
This past Sunday was the third day of the American Society of Clinical Oncology (ASCO) 2011 annual meeting, and it was a particularly busy day for meeting attendees interested in multiple myeloma.
The Beacon published an update yesterday covering two sets of presentations made at Sunday’s oral session about multiple myeloma. This article covers the other set of presentations, which was about myeloma bone disease, as well as material from an afternoon education session focused on myeloma.
Myeloma Bone …
According to the results of a large Phase 3 clinical trial, Zometa increases overall and progression-free survival rates among multiple myeloma patients compared to Bonefos and is more effective in preventing bone loss and fractures. Additonally, the trial found that inclusion of thalidomide as part of an induction regimen further improved responses.
Dr. Gareth Morgan of the Royal Marsden Hospital in London presented the results, recently published in The Lancet (abstract), at the American Society of Hematology (ASH) annual meeting in Orlando today.
“I think it is incredibly compelling …
The third day of the American Society of Clinical Oncology (ASCO) 2010 annual meeting in Chicago was tailor-made for morning people interested in multiple myeloma. The key myeloma-related activity on Sunday, June 6 was a morning abstract session starting at 9:30 a.m. Nine abstracts were presented and discussed over the course of three hours.
The first two presentations dealt with Velcade (bortezomib)-related research.
Dr. Antonio Palumbo of the University of Turin presented the results of the first study. It compared two regimens for the treatment of newly diagnosed elderly myeloma patients. The first …